Kristie L. Kahl
Articles
Tivozanib Tolerability Shows Potential Advantage for Patients with Advanced RCC
May 20, 2020
Video
Oncology Nursing News sat down with Brian Rini, MD, from the Vanderbilt-Ingram Cancer Center (VICC), to discuss results from the phase III TIVO03 trial, and its potential impact on patients with relapsed or refractory renal cell carcinoma.
Integrated Geriatric Assessment Optimizes Care for Older Adults with Cancer
May 14, 2020
Article
By integrating a comprehensive geriatric assessment with geriatrician-led management care researchers found an improved quality of life for older adults with cancer.
FDA Approves Encorafenib Plus Cetuximab for Metastatic CRC with BRAF V600E Mutation
April 09, 2020
Article
The FDA approved the combination use of encorafenib and cetuximab for the treatment of adult patients with BRAFV600E-positive metastatic colorectal cancer.
FDA Approves Pemetrexed for Injection for Nonsquamous Non-Small Cell Lung Cancer
February 10, 2020
Article
The agency granted full approval to pemetrexed for injection (Pemfexy), a liquid injection and branded alternative to Alimta, for nonsquamous NSCLC.
FDA Grants Priority Review to Belantamab Mafodotin for Relapsed/Refractory Myeloma
January 21, 2020
Article
The agency granted the immunoconjugate targeting B-cell maturation antigen priority review to belantamab mafodotin for the treatment of heavily pre-treated patients with relapsed or refractory multiple myeloma.
FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC
January 21, 2020
Article
Oncoprex in combination with osimertinib received fast track designation from the FDA to treat patients with non-small cell lung cancer.
FDA Grants Priority Review to Rucaparib for BRCA1/2-Positive mCRPC
January 16, 2020
Article
The FDA granted priority review to rucaparib for the treatment of adult patients with BRCA1/2-mutant recurrent, metastatic castration-resistant prostate cancer.
FDA Grants Priority Review to Frontline Nivolumab-Ipilimumab Combo for NSCLC
January 16, 2020
Article
The FDA accepted and granted priority review to the supplemental biologics license application for nivolumab in combination with ipilimumab for the first-line treatment of patients with metastatic or recurrent non-small cell lung cancer.
T-DXd Could Be New Standard of Care for Breast Cancer Subset
December 12, 2019
Article
Trastuzumab deruxtecan had an ORR rate of nearly 61% for patients with advanced HER2-positive breast cancer.